| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | 2.067 | 30.308 | 1.014 | 809 | 3.217 |
| Total Income - EUR | - | - | - | - | - | 14.157 | 33.182 | -5.834 | -3.835 | 2.013 |
| Total Expenses - EUR | - | - | - | - | - | 18.320 | 17.413 | 7.972 | 6.812 | 4.897 |
| Gross Profit/Loss - EUR | - | - | - | - | - | -4.162 | 15.769 | -13.806 | -10.647 | -2.884 |
| Net Profit/Loss - EUR | - | - | - | - | - | -4.227 | 15.203 | -13.837 | -10.647 | -2.884 |
| Employees | - | - | - | - | - | 0 | 1 | 0 | 0 | 0 |
Check the financial reports for the company - Proel Biotech S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | 17.838 | 13.462 | 9.094 | 4.901 | 1.712 |
| Current Assets | - | - | - | - | - | 20.979 | 36.567 | 27.148 | 14.504 | 11.685 |
| Inventories | - | - | - | - | - | 15.766 | 15.873 | 9.028 | 4.351 | 2.465 |
| Receivables | - | - | - | - | - | 2.067 | 13.485 | 13.316 | 10.026 | 9.179 |
| Cash | - | - | - | - | - | 3.146 | 7.209 | 4.804 | 127 | 41 |
| Shareholders Funds | - | - | - | - | - | -4.186 | 11.110 | -2.692 | -13.331 | -16.140 |
| Social Capital | - | - | - | - | - | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | 43.003 | 38.918 | 38.934 | 32.735 | 29.537 |
| Income in Advance | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "3250 - 3250" | |||||||||
| CAEN Financial Year |
3250
|
|||||||||
Comments - Proel Biotech S.r.l.